尿液山梨醇与木糖醇诊断SORD缺乏相关神经病
本研究纳入19例临床和基因确诊的SORD相关神经病患者及715例参考样本,采用气相色谱-质谱法检测尿山梨醇和木糖醇排泄。结果显示患者尿山梨醇和木糖醇中位数显著高于参考人群,两者联合对SORD相关神经病诊断的敏感性和特异性均达100%,且无症状杂合携带者水平正常。
要点
- 尿山梨醇和木糖醇联合检测对SORD相关神经病诊断敏感性和特异性均达100%。
- 患者尿山梨醇中位数638 mmol/mol肌酐,木糖醇中位数1577 mmol/mol肌酐。
- 无症状杂合携带者尿山梨醇/木糖醇水平正常,有助于鉴别。
核心结论
- 尿液山梨醇和木糖醇分析对SORD缺乏相关神经病的筛查和诊断具有临床实用性。
- 木糖醇排泄升高是SORD缺乏的首个临床信息性生物标志物,可能提高生化检测的特异性。
研究设计与样本
- 研究纳入来自7个学术医学中心和1个非营利专科护理中心的确诊或疑似SORD相关神经病患者。
- 采用临床验证的气相色谱-质谱法检测尿液山梨醇和木糖醇排泄,并评估了700余例参考样本。
- 通过标准化问卷收集临床和分子遗传学资料。
主要发现
- 19例确诊患者(中位年龄31岁,47%女性)尿山梨醇中位数638 mmol/mol肌酐(疾病范围第1百分位=456;参考中位数=7,参考第99百分位=198)。
- 尿木糖醇中位数1577 mmol/mol肌酐(疾病范围第1百分位=1242;参考中位数=7,参考第99百分位=102)。
- 山梨醇与木糖醇联合在本患者队列中诊断SORD相关神经病的敏感性和特异性均为100%。
- 4例临床表型相符者尿山梨醇/木糖醇异常(2例意义未明变异,2例单杂合致病变异),而11例无症状杂合携带者水平正常。
关键数值与推荐
- 尿山梨醇中位数638 mmol/mol肌酐,疾病范围第1百分位456 mmol/mol肌酐,参考中位数7,参考第99百分位198。
- 尿木糖醇中位数1577 mmol/mol肌酐,疾病范围第1百分位1242 mmol/mol肌酐,参考中位数7,参考第99百分位102。
- 联合检测的敏感性和特异性均为100%。
临床怎么用
- 对于临床疑似SORD相关神经病的患者,可考虑检测尿液山梨醇和木糖醇以辅助诊断。
- 尿山梨醇和木糖醇联合检测有助于区分患者与无症状杂合携带者。
局限性
- 研究样本量较小(19例确诊患者),需更大规模验证。
- 4例临床表型相符但基因型不明确者的结果需进一步解读。
- 参考样本来自残余临床样本,可能存在选择偏倚。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND OBJECTIVES: Sorbitol dehydrogenase (SORD) deficiency, due to biallelic loss-of-function variants in the SORD gene, is a recently recognized cause of autosomal recessive hereditary neuropathy. Specific diagnosis is difficult on clinical grounds alone, and molecular genetic testing of SORD is complicated by the presence of a pseudogene. Biochemical testing of serum sorbitol is suggested as a potential biomarker. We report a novel urine biochemical profile of elevated excretion of sorbitol and a second polyol, xylitol, to aid in the identification of individuals with SORD-related neuropathy. METHODS: Patients with confirmed or suspected SORD-related neuropathy were recruited by clinicians from 7 academic medical centers and 1 nonprofit specialty care center. Urine was analyzed by a clinically validated, gas chromatography-mass spectrometry assay to measure sorbitol and xylitol excretion. Over 700 reference samples were evaluated from residual clinical samples. Clinical and molecular findings were gathered using a standardized questionnaire. RESULTS: Nineteen individuals with a clinical and genetic diagnosis of SORD-related neuropathy (median age 31 years, 47% female) and 715 reference samples were used to determine the initial performance of this index urine test. The median sorbitol excretion in affected individuals was 638 mmol/mol creatinine (1st percentile of disease range = 456; reference median = 7, reference 99th percentile = 198). The median xylitol excretion was 1,577 mmol/mol creatinine (1st percentile of disease range = 1,242; reference median = 7, reference 99th percentile = 102). In this patient cohort, the combination of sorbitol and xylitol yielded 100% sensitivity and specificity for SORD-related neuropathy. Four additional individuals who had clinical phenotypes compatible with SORD-related neuropathy had abnormal urine sorbitol/xylitol profile, 2 with genotypes involving a variant of unknown significance in SORD and 2 with a single heterozygous pathogenic SORD variant detected, whereas normal urine sorbitol/xylitol levels were observed in 11 asymptomatic, heterozygous carriers. DISCUSSION: These data demonstrate the clinical utility of urine sorbitol and xylitol analysis in the screening and diagnosis of SORD deficiency-related neuropathy. In addition, this is the first description of elevated xylitol in SORD deficiency as a clinically informative biomarker, which may increase the specificity of biochemical testing.
引用
- Bontrager JE, White AL, Brigatti KW, et al. Urine Sorbitol and Xylitol for the Diagnosis of Sorbitol Dehydrogenase Deficiency-Related Neuropathy. Neurology. 2025. PMID: 41223342. doi:10.1212/WNL.0000000000214425
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。